Drug Patents owned by Horizon

1. Drug name - DUEXIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8449910 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8067451 HORIZON Methods and medicaments for administration of ibuprofen Jul, 2026

(3 years from now)

US8501228 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8318202 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

US8309127 HORIZON Stable compositions of famotidine and ibuprofen Jul, 2026

(3 years from now)

Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient

Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
26.6MG;800MG TABLET;ORAL Prescription

2. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871809 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9168304 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9066913 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9220784 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9168305 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9132110 HORIZON Treatment of pain with topical diclofenac Oct, 2027

(5 years from now)

US9339551 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9539335 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US8563613 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9101591 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9339552 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US8252838 HORIZON Diclofenac topical formulation Apr, 2028

(5 years from now)

US9370501 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8618164 HORIZON Treatment of pain with topical diclofenac compounds Jul, 2029

(6 years from now)

US8741956 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8217078 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US9375412 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US9415029 HORIZON Treatment of pain with topical diclofenac Jul, 2029

(6 years from now)

US8546450 HORIZON Treatment of pain with topical diclofenac compounds Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac sodium for treating pain; Use of topical diclofenac for treating pain; Use of topical diclofenac on a joint for treating osteoarthritis; Use of topical diclofenac on the knee and a second topical prescription medication on the same knee; Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% SOLUTION;TOPICAL Prescription

3. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

EP2535044B1 HORIZON Enterically Coated Cysteamine Bitartrate And Cystamine
Jan, 2027

(4 years from now)

EP2535044A1 HORIZON Enterically Coated Cysteamine Bitartrate And Cystamine
Jan, 2027

(4 years from now)

EP1919458A4 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458B3 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458B1 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458A2 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198882 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9192590 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9192590

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US8026284 HORIZON Enterically coated cystamine, cysteamine and derivatives thereof Sep, 2027

(4 years from now)

US8026284

(Pediatric)

HORIZON Enterically coated cystamine, cysteamine and derivatives thereof Mar, 2028

(5 years from now)

US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Jun, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same Dec, 2034

(12 years from now)

US10548859 HORIZON Methods for storing Cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10328037 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10143665 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

US10905662 HORIZON Methods for storing cysteamine formulations and related methods of treatment Aug, 2036

(13 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

4. Drug name - RAYOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8394407 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US9186332 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US9040085 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US8309124 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US9504699 HORIZON Delayed-release glucocorticoid treatment of rheumatoid disease Aug, 2027

(4 years from now)

US8168218 HORIZON Delayed release tablet with defined core geometry Jan, 2028

(5 years from now)

Drugs and Companies using PREDNISONE ingredient

Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET, DELAYED RELEASE;ORAL Prescription
2MG TABLET, DELAYED RELEASE;ORAL Prescription
5MG TABLET, DELAYED RELEASE;ORAL Prescription

5. Drug name - VIMOVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6926907 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs Feb, 2023

(4 months from now)

US9393208 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof Sep, 2029

(6 years from now)

US9220698 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof Mar, 2031

(8 years from now)

US8945621 HORIZON Method for treating a patient at risk for developing an NSAID-associated ulcer Oct, 2031

(9 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE;375MG TABLET, DELAYED RELEASE;ORAL Prescription
EQ 20MG BASE;500MG TABLET, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.